Overview

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.
Phase:
Phase 1
Details
Lead Sponsor:
Philogen S.p.A.
Treatments:
Doxorubicin
Liposomal doxorubicin